Divi's Laboratories Q1 Results: Cons PAT jumps 21% YoY to Rs 430 crore, misses estimates

New Delhi: Divi's Laboratories reported a consolidated net profit of Rs 430 crore for the quarter ended June 30, 2024, which was up by 21 per cent over Rs 356 crore reported by the company in the year ago period. It was lower than Street's estimates of Rs 448 crore.

The consolidated revenue from operations stood at Rs 2,118 crore, which was higher by 19 per cent versus Rs 1,778 crore reported by the multinational pharma company in the corresponding quarter of the last financial year.

Divi's Laboratories earned a total income of Rs 2,197 crores for the first quarter of the year 2024-25 on a consolidated basis as against an income of Rs 1,859 crores for the corresponding quarter of last year.

Profit before Tax (PBT) for the current quarter amounted to Rs 604 crores as against a PBT of Rs 492 crores for the corresponding quarter of the last year and a PBT of Rs 713 crores for the fourth quarter.

The pharma major also reported a forex loss for the current quarter amounted at Rs 1 crore as against a gain of Rs 3 crores during the corresponding quarter of the last year.

On the standalone basis, the PAT in the reported quarter stood at Rs 430 crore which was up by nearly 25 per cent versus Rs 345 crore reported in Q1FY24. Meanwhile, the standalone revenue in the said quarter was reported at Rs 2,142 crore as against Rs 1,810 crore in Q1FY24. This was an 18 per cent uptick on the YoY basis.

The earnings were announced on Saturday and Divi's Laboratories' shares had ended at Rs 4,973.05 on the NSE on Friday, gaining Rs 85.15 or 1.74 per cent over the Thursday closing price.